NCT03342261View on ClinicalTrials.gov

Benefit of DAA Therapy in HCV Monoinfected and HIV-HCV Coinfected Patients With Mixed Cryoglobulinemia

CompletedOBSERVATIONAL
Enrollment

47

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

November 1, 2017

Study Completion Date

November 1, 2017

Conditions
Hepatitis C, ChronicMixed Cryoglobulinemia
Interventions
DRUG

DAA treatment

Patients were treated with direct-acting antiviral (DAA) treatment for 12 or 24 weeks

Trial Locations (1)

69004

Hospices Civils de Lyon - Croix-Rousse Hospital, Lyon

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT03342261 - Benefit of DAA Therapy in HCV Monoinfected and HIV-HCV Coinfected Patients With Mixed Cryoglobulinemia | Biotech Hunter | Biotech Hunter